Newton Fund - Accelerating cost-effective development of improved treatments for COPD and other respirtory diseases in China

点击翻译按钮获取中文摘要

This project focuses on cost effective health care provision for debilitating respiratory diseases, and especially chronic obstructive pulmonary disease (COPD). COPD currently affects 1 in 12 of the Chinese population over 40. Frequently patients respond poorly to current treatment due to drug resistance. Our innovative approach will overcome this issue with an inexpensive, simple, efficacious, dry powder inhaler (DPI) device containing a novel combination of two existing drugs. Innovative supercritical fluid (SCF) technology uniquely provides the ability to prepare the high specification drug powders required. Essential knowledge requirements for the project will be met by bridging leading centres - Crystepharma and Imperial College in the UK with SIMM and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. in China. Outcomes will include ‘first in man’ studies for the new DPI, and creating a preclinical testing centre and SCF manufacturing facilities in China. In addition to the COPD product, a range of improved drug/device patient inhaled products will be developed aimed to treat cost effectively other widespread respiratory disease challenges in China.